Blog
About

4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The objective was to evaluate the safety and effectiveness of soft-tissue augmentation of calcium hydroxylapatite (Radiesse) in patients with facial lipoatrophy secondary to human immunodeficiency virus disease.

          Related collections

          Author and article information

          Journal
          Plast. Reconstr. Surg.
          Plastic and reconstructive surgery
          Ovid Technologies (Wolters Kluwer Health)
          1529-4242
          0032-1052
          Sep 2006
          : 118
          : 3 Suppl
          Affiliations
          [1 ] Chelsea Eye and Cosmetic Surgery Associates, New York, NY 10011, USA.
          Article
          00006534-200609011-00008
          10.1097/01.prs.0000234847.36020.52
          16936543

          Comments

          Comment on this article